Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 12/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PGC | P20142 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27210404 | 0.92 | TRHR (0.54) | TRHRRENACE2ACEPGC | |
| SCHEMBL27210409 | 0.92 | TRHR (0.54) | TRHRRENACE2ACEPGC | |
| SCHEMBL27705635 | 0.82 | HDAC8 (0.44) | RENPGCLNPEP | |
| SCHEMBL31649400 | 0.82 | DPP4 (0.53) | TRHRRENACE2PGCDPP4 | |
| SCHEMBL30839655 | 0.81 | DPP4 (0.66) | TRHRRENDPP4 | |
| SCHEMBL7268512 | 0.80 | KLK5 (0.69) | KLK5ACEF2PRSS1 | |
| SCHEMBL12658455 | 0.80 | KLK5 (0.69) | KLK5ACEF2PRSS1 | |
| SCHEMBL28002552 | 0.80 | KLK5 (0.69) | KLK5ACEF2PRSS1 | |
| SCHEMBL28002546 | 0.80 | KLK5 (0.69) | KLK5ACEF2PRSS1 | |
| SCHEMBL16667799 | 0.79 | KLK5 (0.58) | KLK5ACEF2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | TRHR 619/4885REN 821/4885KLK5 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.